-
Jan 6, 2025 | 
nature.com | Amy H. Comander |Steven J Isakoff |Beverly Moy |Seth A. Wander |Minetta C. Liu |Leif W. Ellisen
AbstractOptimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules.
-
Oct 31, 2024 | 
targetedonc.com | Jordyn Sava |Seth A. Wander
October 31, 2024By In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
-
Oct 8, 2024 | 
onclive.com | Seth A. Wander
CommentaryVideoOctober 8, 2024Author(s):Seth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.
-
Oct 4, 2024 | 
onclive.com | Seth A. Wander
CommentaryVideoOctober 4, 2024Supplements and Featured PublicationsExacting the Role of Novel Endocrine Therapies in ER+ Metastatic Breast CancerAuthor(s):Seth Wander, MD, PhD, discusses the present limitations of first- and later-line therapy for HR+ metastatic breast cancer.
-
Aug 23, 2024 | 
nature.com | Seth A. Wander
AbstractAnti-oestrogen-based therapies, often combined with a CDK4/6 inhibitor, are the current standard-of-care first-line therapy for patients with advanced-stage hormone receptor-positive (HR+) breast cancer. Resistance to anti-oestrogen agents inevitably occurs, mediated by oestrogen receptor (ER)-dependent or ER-independent mechanisms that drive tumour progression.
-
Mar 6, 2024 | 
onclive.com | Seth A. Wander
March 6, 2024Seth Wander, MD, PhD, discusses the ELAINE-1, ELAINE-2, and ELAINE-3 trials in patients with ER-positive, HER2-negative metastatic breast cancer.
-
Jan 5, 2024 | 
onclive.com | Seth A. Wander
Seth Wander, MD, PhD, medical oncologist, Massachusetts General Hospital, instructor, medicine, Harvard Medical School, discusses findings from an analysis of baseline genomic alterations in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who were enrolled in the single-arm, phase 2 ELAINE-2 trial (NCT04432454) of lasofoxifene plus abemaciclib (Verzenio).
-
Oct 4, 2023 | 
onclive.com | Seth A. Wander
Seth Wander, MD, PhD, instructor, medicine, Harvard Medical School, medical oncologist, the Massachusetts General Hospital, discusses the evaluation of vepdegestrant (ARV-471), a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in patients with advanced ER-positive/HER2-negative breast cancer.
-
Jul 27, 2023 | 
onclive.com | Seth A. Wander
Seth Wander, MD, PhD, medical oncologist, Massachusetts General Hospital; instructor, medicine, Harvard Medical School, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients.
-
Feb 10, 2023 | 
onclive.com | Seth A. Wander
Seth Wander, MD, PhD, medical oncologist, the Massachusetts General Hospital, instructor in Medicine, Harvard Medical School, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1mutations in breast cancer.
